Saturday, December 13, 2025
ADVT 
India

Trump tariff actions 'unfair, unjustified', national interest top priority: India

Darpan News Desk IANS, 06 Aug, 2025 10:16 AM
  • Trump tariff actions 'unfair, unjustified', national interest top priority: India

India on Wednesday reiterated that the latest tariff actions by US President Donald Trump are "unfair, unjustified and unreasonable". 

Trump has signed an executive order imposing an additional 25 per cent tariff on imports from India, citing the country’s continued purchase of Russian oil.

"We reiterate that these actions are unfair, unjustified, and unreasonable. India will take all actions necessary to protect its national interests," an MEA spokesperson said in a statement.

The United States has in recent days targeted India’s oil imports from Russia.

"We have already made clear our position on these issues, including the fact that our imports are based on market factors and done with the overall objective of ensuring the energy security of 1.4 billion people of India," the MEA spokesperson said.

"It is therefore extremely unfortunate that the US should choose to impose additional tariffs on India for actions that several other countries are also taking in their own national interest," said the official statement.

In the executive order, Trump said the decision is aimed at strengthening measures taken under earlier sanctions against Russia following its actions in Ukraine.

The order states that India is directly or indirectly importing oil from Russia, which the US considers a threat to its national security and foreign policy.

"Accordingly, and as consistent with applicable law, articles of India imported into the customs territory of the United States shall be subject to an additional ad valorem rate of duty of 25 per cent," the order reads.

The new tariffs will be applied to all eligible Indian goods entering the US from 21 days after the order’s signing, except for shipments already in transit before the deadline and cleared before September 17.

Picture Courtesy: IANS 

MORE India ARTICLES

Punjab Cabinet allows conversion of industrial plots into hospitals, hotels

Punjab Cabinet allows conversion of industrial plots into hospitals, hotels
A spokesperson for the Chief Minister's Office said that earlier conversion policies were introduced in 2008, 2016, and 2021.

Punjab Cabinet allows conversion of industrial plots into hospitals, hotels

Shubhanshu Shukla enters space station, a giant leap for India

Shubhanshu Shukla enters space station, a giant leap for India
After a long and ardent wait of 41 years, India now has an astronaut in space. Lucknow-born Shukla is also the second Indian in space after Rakesh Sharma, who flew to space in 1984.

Shubhanshu Shukla enters space station, a giant leap for India

India’s FDI inflows surge to $8.8 billion in April

India’s FDI inflows surge to $8.8 billion in April
India ranked 16th globally in FDI inflows and recorded $114 billion in greenfield investment in digital economy sectors over the last five years (2020-2024), the highest among all countries in the Global South, the bulletin states.

India’s FDI inflows surge to $8.8 billion in April

High-level meeting to be held in Pahalgam to review tourism

High-level meeting to be held in Pahalgam to review tourism
The Union Ministry of Culture and Tourism is going to hold a review meeting of tourism secretaries of all states on July 7 and 8 in Pahalgam to revive tourism in the Kashmir Valley.

High-level meeting to be held in Pahalgam to review tourism

Food, nutrition, muscle loss in microgravity among Shubhanshu Shukla’s experiments in space

Food, nutrition, muscle loss in microgravity among Shubhanshu Shukla’s experiments in space
After being deferred at least six times, Shukla finally launched to ISS on Wednesday at 2:31 a.m. EDT (12 noon IST), from Launch Complex 39A at NASA’s Kennedy Space Center in Florida, aboard a new SpaceX Dragon spacecraft on the company’s Falcon 9 rocket.

Food, nutrition, muscle loss in microgravity among Shubhanshu Shukla’s experiments in space

Novo Nordisk launches weight-loss drug Wegovy in India, priced at Rs 4,336.25 per dose

Novo Nordisk launches weight-loss drug Wegovy in India, priced at Rs 4,336.25 per dose
Wegovy, a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA), is the first and only weight management medication in India.

Novo Nordisk launches weight-loss drug Wegovy in India, priced at Rs 4,336.25 per dose